Breast adenocarcinoma
Item
histologically proven breast adenocarcinoma
boolean
C0858252 (UMLS CUI [1])
Measurable Disease | Evaluable Disease
Item
evaluable or measurable metastases
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
HER2/Neu Status Immunohistochemistry | HER2/Neu Negative Fluorescent in Situ Hybridization | HER2/Neu Negative Chromogenic in situ Hybridization
Item
her-2 status 0 or 1 in immnohistochimy or negative in fish/cish
boolean
C1512413 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
C2348908 (UMLS CUI [2,1])
C0162789 (UMLS CUI [2,2])
C2348908 (UMLS CUI [3,1])
C1516514 (UMLS CUI [3,2])
Anthracyclines | taxane
Item
previously treated with anthracyclines and taxanes
boolean
C0282564 (UMLS CUI [1])
C0215136 (UMLS CUI [2])
Age
Item
age > = 18 y
boolean
C0001779 (UMLS CUI [1])
Chemotherapy Regimen Quantity Neoplasm Metastasis
Item
no more than two previous chemotherapy regimens for metastases
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
Central Nervous System Involvement
Item
no nervous central system involvement
boolean
C4050309 (UMLS CUI [1])
Hormone Therapy To be stopped
Item
hormonal therapy must have been stopped two weeks before enrollment
boolean
C0279025 (UMLS CUI [1,1])
C1272691 (UMLS CUI [1,2])
Biological function
Item
adequate biologic function
boolean
C3714634 (UMLS CUI [1])
performance status
Item
performance status oms < = 2
boolean
C1518965 (UMLS CUI [1])
Informed Consent
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
Malignant Neoplasms | Basal cell carcinoma | Carcinoma in situ of uterine cervix
Item
history of other malignancies, except basocellular cancer, in situ cervix carcinoma
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0851140 (UMLS CUI [3])
Gastrointestinal Disease Affecting Absorption capecitabine
Item
gastro intestinal disease that might affect absorption of capecitabine
boolean
C0017178 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C2347023 (UMLS CUI [1,3])
C0671970 (UMLS CUI [1,4])
Heart failure Uncontrolled | Angina Pectoris Uncontrolled
Item
cardiac failure or angina pectoris uncontrolled
boolean
C0018801 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0002962 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
Hypersensitivity capecitabine | Fluorouracil allergy | Hypersensitivity capecitabine Excipient | Hypersensitivity Fluorouracil Excipient
Item
hypersensitivity for capecitabine, fluorouracil, or one of their excipient
boolean
C0020517 (UMLS CUI [1,1])
C0671970 (UMLS CUI [1,2])
C0570698 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0671970 (UMLS CUI [3,2])
C0015237 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0016360 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
Dihydropyrimidine Dehydrogenase Deficiency
Item
known dihydropyrimidine dehydrogenase (dpd) deficiency
boolean
C1959620 (UMLS CUI [1])
cancer treatment | Hormone Therapy
Item
concomitant anticancer therapy (included hormonotherapy)
boolean
C0920425 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
Therapeutic radiology procedure
Item
concomitant radiotherapy
boolean
C1522449 (UMLS CUI [1])
sorivudine | sorivudine Analog
Item
treatment with sorivudine and analogs
boolean
C0207628 (UMLS CUI [1])
C0207628 (UMLS CUI [2,1])
C0243071 (UMLS CUI [2,2])
Pregnancy | Breast Feeding | Contraceptive methods Patient need for | Hormone Therapy
Item
pregnant or breast feeding patients. contraception methods excluding hormonal treatment is required.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [3,1])
C0686904 (UMLS CUI [3,2])
C0279025 (UMLS CUI [4])
Study Subject Participation Status | research study
Item
inclusion in an experimental protocol within 30 days
boolean
C2348568 (UMLS CUI [1])
C0681814 (UMLS CUI [2])